Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01847495|
Recruitment Status : Withdrawn (no patients enrolled)
First Posted : May 7, 2013
Last Update Posted : February 23, 2018
The purpose of this study is to determine the effects of CyberKnife stereotactic body radiotherapy in combination with irinotecan chemotherapy in patients with colon or rectal cancer that has spread to the liver.
Conventional radiation therapy has a limited role in the treatment of patients with liver metastases because the radiation doses are limited by liver toxicity. The CyberKnife system is a type of radiation machine that precisely focuses large doses of x-rays on the tumor, so that injury from radiation to the nearby normal tissue will be minimal. It is approved by the U.S. Food and Drug Administration to treat tumors, lesions and conditions anywhere in the body when radiation therapy is required. While the device is no longer classified as "investigational", the best treatment dose and times are still being evaluated.
Chemotherapy delivered with radiation therapy can increase the effectiveness of treatment, and may allow for a lower dose of radiation therapy to be utilized, thereby limiting negative side effects.
In this study, patients will receive Cyberknife radiosurgery directed to liver metastasis for 3-5 treatments, given every other day. Irinotecan 40mg/m2 will be administered intravenously daily for 3-5 days (5 treatments within 10 elapsed days), and prior to radiation therapy. Patients will have follow-up visits at months 1,2,4,6,9,12,15,18, 24, 30, 36, and every 6 months thereafter for 3 years.
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer||Drug: Irinotecan Radiation: CyberKnife||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prospective Evaluation of Low-dose Irinotecan and Cyberknife® Stereotactic Body Radiotherapy in the Treatment of Patients With Colorectal Cancer and Limited Liver Metastasis|
|Study Start Date :||October 2013|
|Estimated Primary Completion Date :||October 2020|
|Estimated Study Completion Date :||October 2025|
Experimental: Low-Dose Irinotecan & CyberKnife SBRT
Irinotecan 40mg/m2 x 3-5 days + CyberKnife SBRT 45-60Gy x 3-5 fractions
40mg/m2 x 3-5 days
45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
Other Name: Stereotactic Radiosurgery
- Number of participants with adverse events related to toxicities from concurrent SBRT and irinotecan [ Time Frame: 3 years ]
- Tumor response rate [ Time Frame: 3 years ]
- Progression free survival [ Time Frame: 3 years ]
- Overall survival [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01847495
|United States, Illinois|
|Advocate Lutheran General Hospital|
|Park Ridge, Illinois, United States, 60068|
|Study Chair:||Arica Hirsch, MD||Advocate Lutheran General Hospital|
|Study Chair:||James Ruffer, MD||Advocate Lutheran General Hospital|
|Study Chair:||Jacob Bitran, MD||Advocate Lutheran General Hospital|
|Study Chair:||Edward S James, M.D.||Advocate Lutheran General Hospital|